NCT03229174 is a Phase 4 clinical trial of Droxidopa in Parkinson Disease, sponsored by William Ondo, MD.

Who is sponsoring NCT03229174?

NCT03229174 is sponsored by William Ondo, MD.

What drugs are being tested in NCT03229174?

Interventions in NCT03229174: Droxidopa, Placebo.

What condition does NCT03229174 study?

NCT03229174 studies Parkinson Disease, Neurogenic Orthostatic Hypotension.

Is NCT03229174 still recruiting?

NCT03229174 is currently completed. Last updated 6 September 2022.

Last reviewed 2022-09-06 · How we verify

NCT03229174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Completed Phase 4 Last updated 6 September 2022

What this trial tests

Phase 4 trial testing Droxidopa in Parkinson Disease in 17 participants. Completed in 2 February 2022.

Timeline

23 August 2018

Primary endpoint
2 February 2022

2 February 2022

Quick facts

Lead sponsor	William Ondo, MD
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	17
Start date	23 August 2018
Primary completion	2 February 2022
Estimated completion	2 February 2022
Sites	1 location across United States

Drugs / interventions tested

Droxidopa (DROXIDOPA) — full drug profile →
Placebo

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Neurogenic Orthostatic Hypotension — all drugs for Neurogenic Orthostatic Hypotension →

Sponsor

William Ondo, MD — full company profile →

Who can join

Adults 18 to 85, any sex, with Parkinson Disease or Neurogenic Orthostatic Hypotension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug (droxidopa) may improve cerebral perfusion more robustly than systemic BP, possibly by direct action within the CNS vasculature. This study is designed to determine if droxidopa improves cerebral perfusion measures in PD patients with NOH, in addition to peripheral BP measures and subjective responses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Droxidopa

Trials testing the same drug.

NCT04977388 — NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome · Phase 1, PHASE2 · completed
NCT03567447 — Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) · Phase 2 · unknown
NCT03115827 — Norepinephrine-targeted Therapy for Action Control in Parkinson Disease · Phase 4 · completed
NCT03070730 — Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist · Phase 1, PHASE2 · terminated

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other William Ondo, MD trials

Trials by the same sponsor.

NCT05581576 — Pitolisant in Refractory Restless Legs Syndrome · Phase 4 · unknown
NCT05529095 — Sublingual Apomorphine in Refractory Restless Legs Syndrome · Phase 4 · unknown
NCT02509793 — A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) · Phase 4 · unknown
NCT03218969 — Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03229174 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by William Ondo, MD
Last refreshed: 6 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03229174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing